Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights.
Olusegun Isaac AlatiseGregory C KnappAvinash SharmaWalid K ChatilaOlukayode A ArowoloOlalekan OlasehindeOlusola C FamurewaAdeleye D OmisoreAkinwumi O KomolafeOlaejirinde Olaniyi OlaofeAba I KatungDavid E IbikunleAdedeji A EgberongbeSamuel A OlatokeSulaiman O AgodirinOlusola A AdesiyunAdemola AdeyeyeOladapo A KolawoleAkinwumi O OlakanmiKanika AroraJeremy ConstableRonak ShahAzfar BasuniaBrooke SylvesterChao WuMartin R WeiserKen SeierMithat GonenZsofia K StadlerYelena M KemelEfsevia VakianiMichael F BergerTimothy A ChanDavid B SolitJinru ShiaFrancisco Sanchez-VegaNikolaus SchultzMurray F BrennanJ Joshua SmithThomas Peter KinghamPublished in: Nature communications (2021)
Understanding the molecular and phenotypic profile of colorectal cancer (CRC) in West Africa is vital to addressing the regions rising burden of disease. Tissue from unselected Nigerian patients was analyzed with a multigene, next-generation sequencing assay. The rate of microsatellite instability is significantly higher among Nigerian CRC patients (28.1%) than patients from The Cancer Genome Atlas (TCGA, 14.2%) and Memorial Sloan Kettering Cancer Center (MSKCC, 8.5%, P < 0.001). In microsatellite-stable cases, tumors from Nigerian patients are less likely to have APC mutations (39.1% vs. 76.0% MSKCC P < 0.001) and WNT pathway alterations (47.8% vs. 81.9% MSKCC, P < 0.001); whereas RAS pathway alteration is more prevalent (76.1% vs. 59.6%, P = 0.03). Nigerian CRC patients are also younger and more likely to present with rectal disease (50.8% vs. 33.7% MSKCC, P < 0.001). The findings suggest a unique biology of CRC in Nigeria, which emphasizes the need for regional data to guide diagnostic and treatment approaches for patients in West Africa.